Korro Bio Inc
NASDAQ:KRRO
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
31.3
90
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Korro Bio Inc
Korro Bio Inc
Other Equity
Korro Bio Inc
Other Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Korro Bio Inc
NASDAQ:KRRO
|
Other Equity
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Equity
-$2.3B
|
CAGR 3-Years
10%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Equity
$18.4B
|
CAGR 3-Years
526%
|
CAGR 5-Years
175%
|
CAGR 10-Years
61%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Equity
-$336m
|
CAGR 3-Years
25%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-12%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Equity
-$22.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Equity
$60.2m
|
CAGR 3-Years
82%
|
CAGR 5-Years
29%
|
CAGR 10-Years
8%
|
|
Korro Bio Inc
Glance View
Korro Bio Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Cambridge, Massachusetts and currently employs 48 full-time employees. The company went IPO on 2019-10-03. Korro Bio, Inc. is a biopharmaceutical company. The firm discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The firm is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Its Oligonucleotide Promoted Editing of RNA (OPERA) is a foundational platform for RNA editing, which is designed to edit RNA in vivo by delivering an oligonucleotide guide that can target specific RNA sequences. OPERA co-opts the cell’s natural process with its synthetic oligo and catalyzes a single base change to modify protein sequence and function without the need to permanently modify one’s genome. The firm's focus areas include the liver and central nervous system (CNS).
See Also
What is Korro Bio Inc's Other Equity?
Other Equity
0
USD
Based on the financial report for Dec 31, 2023, Korro Bio Inc's Other Equity amounts to 0 USD.
You don't have any saved screeners yet
